About Pheon Therapeutics
Pheon Therapeutics is a clinical-stage Antibody-Drug Conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers, including solid tumors and liquid cancers unresponsive to other treatments. The company leverages two decades of ADC experience with a pipeline of monotherapies targeting novel antigens, including lead asset PHN-010 and PHN-020. Originally incorporated as Femtonix Ltd in 2015 as a King's College London spinout, it relaunched as Pheon Therapeutics in September 2022.
Company details
Funding
Total raised
$188M
Last stage
Series B
Investors
Founders
Paul Jackson
Co-founded Pheon Therapeutics (formerly Femtogenix) in 2015. Earned his PhD in Prof. David Thurston's lab at King's College London, developing ADC payload design methods. Led R&D and business development from the company's foundation.
LinkedInDavid Thurston
Emeritus Professor of Drug Discovery; previously co-founded Spirogen, whose payload technology underpins the approved ADC Zynlonta. Academic origin of the King's College London spinout that became Pheon Therapeutics.
Bertrand Damour
Headed Pheon at launch with 20+ years of biotech management experience. Previously CEO of NBE Therapeutics (acquired by Boehringer Ingelheim for $1.4B in 2020), GeneProt, Mind NRG, and OncoEthix.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.